- Betrixaban represents the first oral and long-lasting treatment to prevent deep vein thrombosis and pulmonary embolisms in acutely ill nonsurgical patients.
- The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer.
- Nevisense is a device intended to help clinicians detect early stages of malignant melanoma.
- The ClearLLab test detects several types of blood and lymphatic cancers.
- Illumina’s next-generation sequencing kit helps clinicians identify which patients are eligible for treatment with Amgen’s cancer drug Vectibix.
More articles on supply chain:
New York City faces critical blood shortage
UPS’ newest delivery vehicles? Golf carts
6 drug, device recalls in June
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.